Skip to content

Study · Randomized controlled trial · 2010

4 results

Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis.

Devogelaer JP, Adler RA, Recknor C, See K, Warner MR, Wong M, Krohn K

The Journal of rheumatology16 Nov 2009Cited by 46 (Europe PMC)

PMID19918047 (opens in a new tab)DOI10.3899/jrheum.090411 (opens in a new tab)PepBankPUB-19918047
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In glucocorticoid-induced osteoporosis with low baseline glucocorticoid doses, lumbar spine BMD increased 8.1% with teriparatide versus 3.6% with alendronate.

    In plain wordsIn patients taking low glucocorticoid doses, spine bone density increased numerically more with teriparatide than with alendronate.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar spine BMD with low glucocorticoid dose
    Study

    n: not reported in source

    Comparator
    Alendronate 10 mg/day in the low baseline glucocorticoid dose category
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg/day · 18 monthsAs given in this study (human).

    Measurements

    Lumbar spine BMD increase
    8.1%
    teriparatide; low baseline glucocorticoid dose
    Lumbar spine BMD increase
    3.6%
    alendronate; low baseline glucocorticoid dose

    Source sentences

    Summary
    LS BMD increases at the low, medium, and high glucocorticoid doses were 8.1%, 6.6%, and 4.6%, respectively, with teriparatide, and 3.6%, 2.8%, and 2.3% with alendronate.
    1 context sentence
    Summary · context
    This post-hoc analysis studied the effect of baseline glucocorticoid dose on the 18-month bone mineral density (BMD) response to teriparatide 20 microg/day or alendronate 10 mg/day in 387 patients with glucocorticoid-induced osteoporosis (GIO) from a randomized, double-blind trial.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In glucocorticoid-induced osteoporosis with medium baseline glucocorticoid doses, lumbar spine BMD increased 6.6% with teriparatide versus 2.8% with alendronate.

    In plain wordsIn patients taking medium glucocorticoid doses, spine bone density increased numerically more with teriparatide than with alendronate.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar spine BMD with medium glucocorticoid dose
    Study

    n: not reported in source

    Comparator
    Alendronate 10 mg/day in the medium baseline glucocorticoid dose category
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg/day · 18 monthsAs given in this study (human).

    Measurements

    Lumbar spine BMD increase
    6.6%
    teriparatide; medium baseline glucocorticoid dose
    Lumbar spine BMD increase
    2.8%
    alendronate; medium baseline glucocorticoid dose

    Source sentences

    Summary
    LS BMD increases at the low, medium, and high glucocorticoid doses were 8.1%, 6.6%, and 4.6%, respectively, with teriparatide, and 3.6%, 2.8%, and 2.3% with alendronate.
    1 context sentence
    Summary · context
    This post-hoc analysis studied the effect of baseline glucocorticoid dose on the 18-month bone mineral density (BMD) response to teriparatide 20 microg/day or alendronate 10 mg/day in 387 patients with glucocorticoid-induced osteoporosis (GIO) from a randomized, double-blind trial.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In glucocorticoid-induced osteoporosis with high baseline glucocorticoid doses, lumbar spine BMD increased 4.6% with teriparatide versus 2.3% with alendronate.

    In plain wordsIn patients taking high glucocorticoid doses, spine bone density increased numerically more with teriparatide than with alendronate.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar spine BMD with high glucocorticoid dose
    Study

    n: not reported in source

    Comparator
    Alendronate 10 mg/day in the high baseline glucocorticoid dose category
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg/day · 18 monthsAs given in this study (human).

    Measurements

    Lumbar spine BMD increase
    4.6%
    teriparatide; high baseline glucocorticoid dose
    Lumbar spine BMD increase
    2.3%
    alendronate; high baseline glucocorticoid dose

    Source sentences

    Summary
    LS BMD increases at the low, medium, and high glucocorticoid doses were 8.1%, 6.6%, and 4.6%, respectively, with teriparatide, and 3.6%, 2.8%, and 2.3% with alendronate.
    1 context sentence
    Summary · context
    This post-hoc analysis studied the effect of baseline glucocorticoid dose on the 18-month bone mineral density (BMD) response to teriparatide 20 microg/day or alendronate 10 mg/day in 387 patients with glucocorticoid-induced osteoporosis (GIO) from a randomized, double-blind trial.

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 04HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome

    In glucocorticoid-induced osteoporosis, relative lumbar spine BMD differences between teriparatide and alendronate did not vary significantly across glucocorticoid dose categories.

    In plain wordsIn patients, spine bone density differences between teriparatide and alendronate did not vary significantly across glucocorticoid dose categories.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeTreatment-by-glucocorticoid dose interaction for lumbar spine BMD
    Study

    n: not reported in source

    Comparator
    Alendronate across glucocorticoid dose categories
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Across the 3 glucocorticoid dose categories, the overall LS BMD increases were different for both treatments combined (p = 0.033), but the relative differences between the treatment groups were not different (interaction, p = 0.52).
    1 context sentence
    Summary · context
    This post-hoc analysis studied the effect of baseline glucocorticoid dose on the 18-month bone mineral density (BMD) response to teriparatide 20 microg/day or alendronate 10 mg/day in 387 patients with glucocorticoid-induced osteoporosis (GIO) from a randomized, double-blind trial.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00051558

Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis

Eli Lilly and Companyn = 428Nov 2002 to Jan 2008

Osteoporosis

Trial pageClinicalTrials.govUpdated 12 Mar 2009

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.